Hemostasis Drugs Flashcards
Hemostasis
Process that halts bleeding after injury to a blood vessel
1.Formation of a platelet plug
2.Production of fibrin
Anticoagulants
•Inhibit the action or formation of clotting factors
•Prevent clot formation
•Clotting cascade: results in fibrin which forms clots
•Anticoagulants are used prophylactically to prevent thrombus (clot formation), and embolus (dislodged clot)
•Have NO EFFECT on existing clots
Heparin
Low-molecular-weight heparins
Warfarin
Direct-Acting Oral Anticoagulants (DOACs)
Antiplatelet drugs
Inhibit platelet aggregation
Prevent platelet plugs
Thrombolytic Drugs
Lyse (break down) existing clots
Hemostatic drugs
Promote blood coagulation
Heparin
Anticoagulants
Heparin: indirectly inhibits activity of Thrombin II
•+ other factors in intrinsic pathway
•Monitored by activated partial thromboplastin times (aPPT)
•aPPT measure of intrinsic pathways and need to be 1.5-2.5 x greater than control
•Parenteral - IV or SC
•Anticoagulant effects reversed by protamine sulfate
low-molecular-weight heparins
•Anticoagulant
•More predictable anticoagulant response
•Do not require frequent laboratory monitoring
•Often given at home: SC in abdomen only
•indirectly inhibits Factor X only
•Drug: Enoxaparin
Warfarin
•Anticoagulant
•Oral only
•Vitamin K agonist (vit K essential for production of clotting factor)
•prothrombin time (PT) and INR (international normalization ratio) monitored by clotting test lab
•Normal INR range: 2–3x control
-Some need to be 2.5-3.5x
•Vitamin K can be given if excessive PT/INR
•Warfarin STRONGLY contraindicated in pregnancy
Anticoagulant client education
•Keep intake of vitamin K constant (tomatoes, dark leafy green vegetables)
•Medical alert bracelet
Nursing indications: warfarin
•Warfarin may be started while the client is still on heparins
•until prothrombin times/INR indicate adequate anticoagulation
Direct-Acting Oral Anticoagulants (DOACs)
•Anticoagulants
Danigatran
•Direct thrombin inhibitor
•PO administration
-Rapid onset, fixed doses, no blood test, few drug interactions, low risk of bleeds
Rivaroxaban
•Direct factor Xa inhibitor
•PO administration
•Similar advantages as dabigatran
Antiplatelet Drugs
•Prevent platelet activation
•Reduce risk of MI, stroke
ASA
•81 mg EC
•Irreversible inhibition of COX in platelets
Clopidogrel
•Irreversible ADP receptor blocker
•Aspirin + clopidogrel combination = additive antiplatelet activity but increased bleeding potential
Thrombolytic Agents
(fibrinolytic agents)
•Drugs that break down preformed clots
•Activate plasminogen and convert it to plasmin, which can digest fibrin
Recombinant tissue plasminogen activator (tPA)
•DRUG: Alteplase
INDICATIONS:
Acute MI, Arterial thrombolysis, DVT, occlusion of shunts or catheters, pulmonary embolus
ADVERSE:
-Bleeds
-Dysrhythmias
Antifibrinolytic Agents
•drugs that act by inhibiting the process that dissolves clots, thereby reducing bleeding.
•Promote clot formation and/or clot maintenance
Aminocaproic acid
•Blocks plasminogen activation
Never used in DIC (disseminated intravascular coagulation)